AMR Market Expected to Reach USD 21.6 B by 2031 as Phage Therapy and AI Combat the "Silent Pandemic"

[Hyderabad, April 18th, 2025]– The Anti-Microbial Resistance Market, valued at 9.4 billion in 2023, will grow at 10.9% to 10.921.6 billion by 2031, as superbugs outpace traditional antibiotics, reports ClearView Market Insights.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-anti-microbial-resistance-market/
2024 Turning Points
- Bacteriophage Renaissance
- The first FDA-approved phage cocktail achieves 100% MRSA clearance.
- CRISPR-engineered phages directly target resistance genes.
- AI Reshapes Drug Discovery
- Exscientia's XAI-101 shows ten times the potency against gram-negative bacteria.
- 3 new AMR targets identified via machine learning.
- Diagnostics Revolution
- 45-minute resistance detection slashes inappropriate antibiotic use.
- Real-time sequencing tracks outbreaks in hospitals.
Regional Responses
- North America (45%): Leading in novel drug incentives.
- Europe (XX%): Phage therapy approvals and stewardship.
- Asia (XX%): Scaling rapid diagnostics to curb misuse.
Executive Insights
"We're fighting evolution with evolution – using phages and AI to outsmart superbugs."
– David Huang, CEO, Adaptive Phage Therapeutics
Roadmap to 2031
- 2025: 50% of US hospitals adopt rapid AMR diagnostics.
- 2027: Phage-antibiotic combos standard for chronic infections.
- 2030: AI-designed drugs target 90% of known resistance mechanisms.
For more insights, visit https://clearviewmarketinsights.com/report-store
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369